Stoke Therapeutics (STOK) Net Margin (2022 - 2025)
Historic Net Margin for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to 360.68%.
- Stoke Therapeutics' Net Margin rose 1793700.0% to 360.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.63%, marking a year-over-year increase of 6497300.0%. This contributed to the annual value of 242.74% for FY2024, which is 9516200.0% up from last year.
- As of Q3 2025, Stoke Therapeutics' Net Margin stood at 360.68%, which was up 1793700.0% from 169.96% recorded in Q2 2025.
- In the past 5 years, Stoke Therapeutics' Net Margin registered a high of 71.19% during Q1 2025, and its lowest value of 1237.2% during Q2 2023.
- For the 4-year period, Stoke Therapeutics' Net Margin averaged around 590.69%, with its median value being 625.57% (2024).
- Per our database at Business Quant, Stoke Therapeutics' Net Margin tumbled by -4729200bps in 2023 and then soared by 9163200bps in 2024.
- Stoke Therapeutics' Net Margin (Quarter) stood at 786.32% in 2022, then dropped by -23bps to 963.56% in 2023, then skyrocketed by 95bps to 47.24% in 2024, then plummeted by -663bps to 360.68% in 2025.
- Its Net Margin was 360.68% in Q3 2025, compared to 169.96% in Q2 2025 and 71.19% in Q1 2025.